Intratumoral Injection of Lipopolysaccharide Causes Regression of Subcutaneously Implanted Mouse Glioblastoma Multiforme

Abstract

OBJECTIVE 

Anecdotal reports documented extended survival times for patients who developed infections at the site of resection of malignant gliomas. Hypothesized mechanisms for this phenomenon include immune responses triggered by lipopolysaccharide (LPS). This investigation assessed whether LPS could produce tumor regression in an in vivo model of malignant glioma.

METHODS 

Delayed brain tumor cells (2 × 10⁶) were injected subcutaneously into female BALB/c mice. LPS (300–500 μg) was injected intratumorally or subcutaneously at a contralateral site on Days 10, 17, and 24. Control animals received phosphate-buffered saline intratumorally or subcutaneously. Mice were killed on Day 28, and tumors were removed. Mean tumor masses for control animals and the two LPS-treated groups (intratumoral or contralateral subcutaneous treatment) were compared. Histological assessments of treated and control tumors were performed.

RESULTS 

Complete or nearly total tumor regression was achieved in all 20 mice with subcutaneous delayed brain tumor cell tumors treated intratumorally with 400 μg of LPS (mean tumor mass of 0.09 ± 0.38 g versus 2.42 ± 2.46 g for control animals, P < 0.0001). Intratumoral administration of 300 μg of LPS or subcutaneous injection of 300 or 400 μg of LPS at a contralateral site resulted in less consistent regression of subcutaneous tumors. Administration of 500 μg of LPS resulted in tumor regression similar to that observed with lower doses but was limited by treatment-related deaths in 40% of animals. Histological assessment revealed lymphocytic infiltration of LPS-treated tumors.

CONCLUSION 

Intratumoral injections of LPS caused dramatic regression of subcutaneously implanted delayed brain tumor cell mouse gliomas. Investigation of this antitumoral effect may improve treatment responses for patients with malignant gliomas.